Preliminary in-vitro evaluation of marketed formulations for antacid activity


  • Pranjali P. Dhawal Department of Animal Biotechnology and Biochemistry, KET’s Scientific Research Centre, Mumbai, Maharashtra, India
  • Siddhivinayak S. Barve KET’s Scientific Research Centre, Mumbai, Maharashtra, India



Antacid, ANC, ANP, Peptic ulceration, PAT


Background: Hydrochloric acid (pH 1.5-3.5) being the major component of gastric acid is produced by parietal cells of stomach. Its secretion is a complex and relatively energetically expensive process. The preservation of acidity of stomach is evidently important because of its implications in peptic and duodenal ulceration.

Methods: In the present study, we attempted to compare the activity of 13 (F1-F13) antacid formulations (5-liquid, 4- quick releases and 4- tablets) by using acid-base neutralization studies. Preliminary antacid test (PAT) was performed to define whether the given formulation falls under the category of antacid wherein the pH of the antacid-acid (HCl) solution should be higher than pH of 3.5. The chosen antacids were further subjected to acid neutralizing capacity (ANC) (reaction between the sample of antacid and amount of acid neutralized by the formulation) and acid neutralizing potential (ANP) which explains the time duration during which a given sample of antacid can maintain pH above 3.5).

Results: Out of the 13 samples tested, two formulations of pastels (F6, F12) were rejected as per the standard protocol of classifying formulations as antacids after screening for PAT. Sample F5 was found to have the highest ANC. F7 also showed highest ANC among the tablets tested. Also, F13 showed better ANC and ANP as in comparison to other quick releases.

Conclusions: Digene products (F5, F7, and F13) showed better antacid properties. This data would provide insights into development of drug, comparison between antacids depending on their chemical formulation and determination of dosage to avoid plausible side effects.


Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. Basic Clin Pharmacol Toxicol. 2005;96(2):94-102.

Maity P, Biswas K, Chattopadhyay I, Banerjee RK, Bandyopadhyay U. The use of neem for controlling gastric hyperacidity and ulcer. Phytother Res. 2009;23(6):747-55..

Díaz-Rubio M. Historical perspective of gastric acid inhibition. Drugs. 2005;65(1):1-6.

Nahar N, Choudhuri MS, Alamgir M. Preliminary in vitro evaluation of some traditional Ayurvedic antacids. Oriental Pharma Experimental Med. 2007;7(4):441-3.

Jakaria M, Zaman R, Parvez M, Islam M, Haque MA, Sayeed MA, et al. Comparative study among the different formulation of antacid tablets by using acid-base neutralization reaction. Global J Pharmacol. 2015;9(3):278-81.

Miederer SE, Wirtz M, Fladung B. Acid neutralization and bile acid binding capacity of hydrotalcite compared with other antacids: An in vitro study. Chinese J Digest Dis. 2003;4(3):140-6.

Hirani JJ, Rathod DA, Vadalia KR. Orally disintegrating tablets: a review. Trop J Pharm Res. 2009;8(2):161-72.

Spivey RJ, Goodhart FW. In vitro acid reactivity of three commercial antacid tablets. Am J Hospital Pharm. 1979;36(5):660-3.

Rosset NF, Rice ML Jr. An in vitro evaluation of the efficacy of tbe more frequently used antacids with particular attention to tablets. Gastroenterology. 1954;26(3):490-5

Katakam P, Rajab J. A Comparative Study of the Acid Neutralizing Capacity of Various Commercially Available Antacid Formulations in Libya. Libyan J Med Res. 2010;7(1):41-9.

Domschke W, Hagel J, Ruppin H, Kaduk B. Antacids and gastric mucosal protection. Scandinavian J Gastroenterol. 1986;21(125):144-50.




How to Cite

Dhawal, P. P., & Barve, S. S. (2019). Preliminary in-vitro evaluation of marketed formulations for antacid activity. International Journal of Basic & Clinical Pharmacology, 9(1), 57–62.



Original Research Articles